| Chengdu's HitGen to Collaborate with Global Blood Therapeutics |
| Author：Yestar Time：2016-01-12 |
| HitGen Ltd, a Chengdu CRO specializing in drug discovery, formed a research collaboration with Global Blood Therapeutics of the US, a clinical-stage biopharma focused on therapeutics for blood-based disorders. HitGen will provide biology, chemistry, and screening on an undisclosed novel GBT target. GBT's lead molecule is a clinical-stage drug candidate that treats the underlying mechanism of sickle cell disease, which was recently granted Orphan Drug designation in the US. |
Prev：Null
Next：Luqa Acquires China Rights to Next-Gen Dermal Filler
Copyright © 2017 Yestar Healthcare Holdings Company Limited Powered By : Yestarcorp 沪ICP备10207132号
沪公网安备 31011202004160号